<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FELIMAZOLE- methimazole tablet, sugar coated </strong><br>Dechra Veterinary Products<br></p></div>
<h1>FELIMAZOLE Coated Tablets<br>Methimazole</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First">For oral use in cats only.</p>
<p><span class="Bold">CAUTION:</span> Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Methimazole is a thioureylene antithyroid drug, which inhibits the synthesis of thyroid hormones.  Methimazole (1-methylimidazole-2-thiol) is a white, crystalline substance that is freely soluble in water.  The chemical formula is C<span class="Sub">4</span>H<span class="Sub">6</span>N<span class="Sub">2</span>S. Molecular weight is 114.16.</p>
<p><span class="Bold">Methimazole Chemical Structure</span></p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2d70b747-314c-4baa-95c4-1734855a1556&amp;name=felimazole-01.jpg"></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATION</h1>
<p class="First">FELIMAZOLE (methimazole) Coated Tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> in cats.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-4"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The starting dose of FELIMAZOLE Coated Tablets is 2.5 mg administered every 12 hours.  Following 3 weeks of treatment, the dose should be titrated to effect based on individual serum total T4 (TT4) levels and clinical response.  Dose adjustments should be made in 2.5 mg increments.  The maximum total dosage is 20 mg per day divided, not to exceed 10 mg as a single administration.</p>
<p>Hematology, biochemistry, and TT4 should be evaluated prior to initiating treatment and monitored after 3 weeks and 6 weeks of treatment.  Thereafter, bloodwork should be monitored every 3 months and the dose adjusted as necessary.  Cats receiving doses greater than 10 mg per day should be monitored more frequently.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Do not use in cats with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to methimazole, carbimazole or the excipient, polyethylene glycol.</p>
<p>Do not use in cats with primary liver disease or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
<p>Do not use in cats with autoimmune disease.  See <a href="#adverse">ADVERSE REACTIONS</a>.</p>
<p>Do not use in cats with hematological disorders (such as <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) or coagulopathies.  See <a href="#adverse">ADVERSE REACTIONS</a>.</p>
<p>Do not use in pregnant or lactating queens.  Laboratory studies in rats and mice have shown evidence of teratogenic and embryotoxic effects of methimazole.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Methimazole has anti-vitamin K activity and may induce <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis without evidence of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.  See <a href="#adverse">ADVERSE REACTIONS</a>.</p>
</div>
<div class="Section" data-sectionCode="50741-8">
<a name="section-7"></a><p></p>
<h1>HUMAN WARNINGS</h1>
<p class="First">Not for use in humans.  Keep out of reach of children.  For use in cats only.</p>
<p>Wash hands with soap and water after administration to avoid exposure to drug.  Do not break or crush tablets.  Wear protective gloves to prevent direct contact with litter, feces, urine, or vomit of treated cats, and broken or moistened tablets.  Wash hands after contact with the litter of treated cats.</p>
<p>Methimazole is a human teratogen and crosses the placenta concentrating in the fetal thyroid gland.  There is also a high rate of transfer into breast milk.  Pregnant women or women who may become pregnant, and nursing mothers should wear gloves when handling tablets, litter or bodily fluids of treated cats.</p>
<p>Methimazole may cause <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gastric distress, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.  In the event of accidental ingestion/<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, seek medical advice immediately and show the product label to the physician.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precau"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Use of FELIMAZOLE Coated Tablets in cats with renal dysfunction should be carefully evaluated.  Reversal of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> may be associated with decreased glomerular filtration rate and a decline in renal function, unmasking the presence of underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.</p>
<p>Due to potentially serious adverse reactions such as hepatopathy, immune mediated <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, cats on methimazole therapy should be monitored closely for any sign of illness including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> or signs of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.  If a cat becomes ill while on FELIMAZOLE Coated Tablets, the drug should be stopped and appropriate hematological and biochemical testing should be done.</p>
<p>Anticoagulants may be potentiated by the anti-vitamin K activity of FELIMAZOLE Coated Tablets.  Concurrent use of phenobarbital may reduce the clinical effectiveness of FELIMAZOLE Coated Tablets.  A reduction in dose of certain drugs (β-adrenergic blocking agents, digitalis glycosides, and theophylline) may be needed when the patient becomes euthyroid.</p>
<p>Methimazole is known to reduce the hepatic oxidation of benzimidazole anthelmintics (e.g. fenbendazole), leading to increased plasma concentration of these anthelmintics when administered concurrently.</p>
<p>FELIMAZOLE Coated Tablets caused delayed maturation of the testes in young male cats in the 12-week safety study.  See <a href="#safety">ANIMAL SAFETY</a>.  The safety of FELIMAZOLE Coated Tablets has not been evaluated in male cats intended for breeding.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In a US field study with 113 cats, the most common adverse reactions included change in food consumption (increase or decrease), <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/loose stool, <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span>, and abnormal vocalization.  Three cats were withdrawn early from the study, one due to unmasking of latent <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> and two due to the development of <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span>.  Over the course of the study there was a decreasing trend in the mean counts of red blood cells, <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> and monocytes; however, means remained within or near normal ranges for the testing laboratory.</p>
<p>In the extended use phase of the US field study with 101 cats, the most common adverse reactions reported in the study above (<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>) were also observed.  Additional signs occurring more frequently in the long-term study were: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>/withdrawn behavior, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, haircoat abnormalities, increased blood urea nitrogen (BUN), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.  Most of the adverse reactions reported were mild and transient.</p>
<p>Serum chemistry and hematology results in the extended use study were consistent with the trends noted during the field study.  The mean alanine transaminase (ALT) was above the reference range at the first two quarterly visits, but within the normal reference range (10-100 U/L) through the next two quarterly visits.  Mean lymphocyte counts decreased consistently during the study period, to slightly below the reference range (1200-8000 cells/mcL) at the fourth quarterly visit.</p>
<p>Sixteen cats experienced elevated ANA titers at one or more points during long-term therapy with FELIMAZOLE Coated Tablets, but the significance was not determined.</p>
<p>Eighteen cats died or were euthanized during the extended use study, four of which may have been related to FELIMAZOLE Coated Tablets due to the unmasking/acceleration of <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>.  See <a href="#precau">PRECAUTIONS</a>.</p>
<p>In a foreign field study with 26 cats using a starting dose of 5 mg twice daily (twice the recommended starting dose), one cat was withdrawn due to <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and facial <span class="product-label-link" type="condition" conceptid="4219876" conceptname="Excoriation">excoriations</span>.  Marked <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> was reported in two cats; the platelet count returned to normal in one cat when FELIMAZOLE Coated Tablets was discontinued.  Two cats collapsed and died within 12 days of starting FELIMAZOLE Coated Tablets at a dose of 5 mg twice daily.  Both cats were reported with <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>; one cat also had <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>.</p>
<p>In a second foreign field study with 78 cats using a starting dose of 2.5 mg twice daily, 4 cats were withdrawn due to suspected adverse reactions to FELIMAZOLE Coated Tablets including <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, cholangiohepatitis, <span class="product-label-link" type="condition" conceptid="4219876" conceptname="Excoriation">excoriations</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.  One cat receiving 2.5 mg three times daily collapsed and died after 8 weeks of treatment.  Adverse reactions included <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.  The most frequently reported adverse reactions included mild, transient, self-limiting <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Foreign Market Experience</h2>
<p class="First">The following events were reported voluntarily during post-approval use of FELIMAZOLE Coated Tablets in foreign markets: facial <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, self-induced <span class="product-label-link" type="condition" conceptid="4219876" conceptname="Excoriation">excoriations</span> of the head and neck, generalized <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and elevation of serum liver enzymes and bilirubin.</p>
<p>If overdosage occurs, stop treatment and give symptomatic and supportive care.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-10"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Methimazole is an antithyroid drug that acts by blocking the biosynthesis of thyroid hormone <span class="Italics">in vivo.</span>  The primary action is to inhibit binding of iodide to the enzyme thyroid peroxidase, thereby preventing the catalyzed iodination of thyroglobulin and T<span class="Sub">3</span> and T<span class="Sub">4</span> synthesis.</p>
<p>FELIMAZOLE Coated Tablets are well absorbed following oral administration.  Maximum plasma concentrations are achieved within 1-1½ hours after dosing and methimazole is rapidly eliminated from the blood (T<span class="Sub">½</span> is approximately 3 hours).  Administration of FELIMAZOLE Coated Tablets in a fasted state enhances absorption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1>EFFECTIVENESS</h1>
<p class="First">In a US effectiveness field study with 113 cats, the product was considered effective if both the TT4 concentration was ≤ 4.0 mcg/dL, and the Investigator's clinical assessment documented clinical improvement.  Of the 105 evaluable cases, 64 (61%) were considered treatment successes.  The decrease in TT4 concentration was significant from the pre-enrollment visit to the Day 42 visit.  A TT4 of ≤ 4.0 mcg/dl occurred in 59.1% and 61.9% of cats on Day 21 and Day 42, respectively.  Investigators assessed 91.8% and 87.6% of cats as clinically improved on Days 21 and 42, respectively.</p>
<p>In the extended use phase of the US effectiveness field study with 101 cats, effectiveness was based on a combination of Investigator's clinical assessment, maintenance of TT4 concentrations at or near the laboratory reference range of 0.8-4.0 mcg/dL, and the presence or absence of adverse reactions.  Mean TT4 concentrations were within or near the laboratory reference range during the first four quarterly visits.  At the first quarterly visit, investigators categorized 80.9% of cats as stable or improved relative to their baseline assessment.  By the fourth quarterly visit, 75.8% were deemed to be stable or improved.  </p>
<p>The average maintenance dose required in the extended use phase was 2.5 mg twice daily, with a minimum of 2.5 mg per cat and a maximum of 15 mg per cat on a daily basis.</p>
</div>
<div class="Section" data-sectionCode="50744-2">
<a name="safety"></a><a name="section-12"></a><p></p>
<h1>ANIMAL SAFETY</h1>
<p class="First">In a 12 week safety study, healthy young cats were dosed with 0, 10, 20, and 30 mg FELIMAZOLE Coated Tablets per day, divided into two doses.  Cats in all treated groups experienced <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, loose stool and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>.  Cats in the 20 and 30 mg/day groups also had facial <span class="product-label-link" type="condition" conceptid="4219876" conceptname="Excoriation">excoriations</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>.  The following hematological changes were seen: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.  The following biochemical changes were seen: increased globulin, increased magnesium, increased blood urea nitrogen, increased creatinine and decreased phosphorus.  There was a dose dependent occurrence of anti-nuclear antibodies.  Most of the clinical pathology changes were mild in nature.  One cat dosed with 20 mg/day experienced a six-fold increase in ALT during the study.  This cat had loose stool, but was otherwise healthy throughout the study.  <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> was seen in this cat at necropsy and the histopathological examination was comparable to other treated cats with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and normal ALT.</p>
<p>Gross necropsy findings in all treated groups included <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, thymus <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> and <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">thyroid hyperplasia</span> and darkening.  Some treated males had delayed maturation of the testes.</p>
<p>The 30 mg/day dose was poorly tolerated and resulted in the clinical deterioration and euthanasia of four of the six cats in that group.  Two of the cats showed signs of immune mediated <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and severe clinical deterioration.  One had been on the drug for 34 days, the other for 9 weeks.  The drug was discontinued in a third cat treated with 30 mg/day while it received supportive care.  It was euthanized on day 55 after becoming anorexic.  This cat had <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (HCT 21.6%) and red blood cell agglutination.  Necropsy showed <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the muscular layer of the stomach and a small erosion in the stomach.  A fourth cat treated with 30 mg/day was euthanized after several days of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> when the decision was made to discontinue dosing in this group.  All 30 mg/day cats that died had generalized <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>.  Necropsies revealed reactive lymph nodes and varying degrees of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> throughout the body.  The remaining 2 cats in the 30 mg/day group were taken off FELIMAZOLE Coated Tablets at week 9 and fully recovered.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13"></a><p></p>
<h1>STORAGE INFORMATION</h1>
<p class="First">Store at controlled room temperature 25°C (77°F) with excursions between 15°–30°C (59°-86°F) permitted.</p>
<p>Keep the container tightly closed in order to protect from moisture.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">FELIMAZOLE Coated Tablets are available in 2.5 mg or 5 mg in bottles containing 100 tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<h1></h1>
<p class="First">NADA 141-292, Approved by FDA</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First"><img alt="Company Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2d70b747-314c-4baa-95c4-1734855a1556&amp;name=felimazole-02.jpg"></p>
<p>Distributed by:<br>Dechra Veterinary Products<br>7015 College Boulevard<br>Suite 525<br>Overland Park, KS  66211</p>
<p>For a copy of the Material Safety Data Sheet (MSDS) or to report adverse reactions call Dechra Veterinary Products at (866) 933-2472.</p>
<p>FELIMAZOLE is a trademark of Dechra Ltd<br>© 2008, Dechra Ltd</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 2.5mg bottle label</h1>
<p class="First"><span class="Bold">2.5 mg</span></p>
<p><span class="Bold">FELIMAZOLE™</span><br>(methimazole) Coated Tablets<br><span class="Bold">100 Tablets</span></p>
<p><span class="Bold">For oral use in cats only.</span></p>
<p><span class="Bold">CAUTION:</span> Federal (USA) law<br>restricts this drug to use by or on<br>the order of a licensed veterinarian.</p>
<p>NADA 141-292, Approved by FDA.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2.5mg bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2d70b747-314c-4baa-95c4-1734855a1556&amp;name=felimazole-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 2.5 mg carton label</h1>
<p class="First"><span class="Bold">2.5 mg</span></p>
<p><span class="Bold">FELIMAZOLE™</span><br>(methimazole)<br>Coated Tablets</p>
<p><span class="Bold">100 Tablets</span></p>
<p>FELIMAZOLE (methimazole) Coated Tablets<br>are indicated for the treatment of<br><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> in cats.</p>
<p><span class="Bold">CAUTION:</span> Federal (USA) law restricts this drug<br>to use by or on the order of a licensed<br>veterinarian.</p>
<p>NADA 141-292, Approved by FDA.</p>
<p>NDC 17033-225-10</p>
<p><span class="Bold">Dechra</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2.5 mg carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2d70b747-314c-4baa-95c4-1734855a1556&amp;name=felimazole-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5mg bottle label</h1>
<p class="First"><span class="Bold">5 mg</span></p>
<p><span class="Bold">FELIMAZOLE™</span><br>(methimazole) Coated Tablets<br><span class="Bold">100 Tablets</span></p>
<p><span class="Bold">For oral use in cats only.</span></p>
<p><span class="Bold">CAUTION:</span> Federal (USA) law<br>restricts this drug to use by or on<br>the order of a licensed veterinarian.</p>
<p>NADA 141-292, Approved by FDA.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5mg bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2d70b747-314c-4baa-95c4-1734855a1556&amp;name=felimazole-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg carton label</h1>
<p class="First"><span class="Bold">5 mg</span></p>
<p><span class="Bold">FELIMAZOLE™</span><br>(methimazole)<br>Coated Tablets</p>
<p><span class="Bold">100 Tablets</span></p>
<p>FELIMAZOLE (methimazole) Coated Tablets<br>are indicated for the treatment of<br><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> in cats.</p>
<p><span class="Bold">CAUTION:</span> Federal (USA) law restricts this drug<br>to use by or on the order of a licensed<br>veterinarian.</p>
<p>NADA 141-292, Approved by FDA.</p>
<p>NDC 17033-250-10</p>
<p><span class="Bold">Dechra</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2d70b747-314c-4baa-95c4-1734855a1556&amp;name=felimazole-06.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FELIMAZOLE 		
					</strong><br><span class="contentTableReg">methimazole tablet, sugar coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17033-225</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>methimazole</strong> (methimazole) </td>
<td class="formItem">methimazole</td>
<td class="formItem">2.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17033-225-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141292</td>
<td class="formItem">06/15/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FELIMAZOLE 		
					</strong><br><span class="contentTableReg">methimazole tablet, sugar coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17033-250</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>methimazole</strong> (methimazole) </td>
<td class="formItem">methimazole</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17033-250-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141292</td>
<td class="formItem">06/15/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Dechra Veterinary Products
							(362142734)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cipla Limited Goa</td>
<td class="formItem"></td>
<td class="formItem">650072015</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ed3397ae-70ac-43f9-97dd-ce02df5aee71</div>
<div>Set id: 2d70b747-314c-4baa-95c4-1734855a1556</div>
<div>Version: 2</div>
<div>Effective Time: 20100302</div>
</div>
</div> <div class="DistributorName">Dechra Veterinary Products</div></p>
</body></html>
